Sanofi is handing over $130 million upfront for the China rights to Arrowhead Pharmaceuticals’ rare metabolic disease ...

Allogene Therapeutics has reported a patient death tied to its anti-CD52 monoclonal antibody used for lymphodepletion in its ...

After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...

AbbVie is ending development of an IL-1 asset as a monotherapy in ulcerative colitis (UC) after a phase 2 study revealed ...

A PD-L1xVEGF bispecific antibody from China’s ImmuneOnco Biopharmaceuticals has shown early promise in shrinking lung tumors, ...

After taking on the title of president earlier this year, Dexcom’s Jake Leach will be stepping into the role of CEO at the ...

D Molecular Therapeutics has posted 60-week data on a gene therapy, providing evidence of durability in diabetic macular edema and sending its stock up more than 40% in premarket trading.

AbbVie has reportedly added Gilgamesh Pharmaceuticals to its shopping list. | AbbVie has reportedly added Gilgamesh ...

Last week, Australian life sciences venture capital firm Brandon Capital closed its largest fund yet, raising A$439 million ...

Medical AI company Cardiosense has claimed FDA clearance for its CardioTag device, a wearable sensor that provides a ...

The FDA has missed the date for Coya Therapeutics’ investigational new drug (IND) application, citing a lack of resources and ...

Cardiff Oncology has reported updated results from its phase 2 colorectal cancer trial, laying out data that it believes can ...